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Introduction: Interactions between the gut microbiota and enteroendocrine cells play
important role in irritable bowel syndrome (IBS). Reduced stem cell densities and their
differentiation into enteroendocrine cells may cause abnormal densities of the duodenal
enteroendocrine cells in IBS patients.
Materials and Methods: We aimed to investigate the effects of fecal microbiota
transplantation (FMT) on stem cell differentiation into enteroendocrine cells as detected
by neurogenin 3, stem cells as detected by Musashi 1, and the enteroendocrine cells in
the duodenum of IBS patients. The study included 16 IBS patients according to Rome III
criteria. Four patients were excluded. The remaining patients (n = 12, four females and
eight males) were divided according to the cause of IBS into post-infectious (n = 6) and
idiopathic (n = 6) IBS. They completed the following questionnaires before and 3 weeks
after FMT: IBS-Symptom Severity Scoring system (IBS-SSS) and IBS-Symptom
Questionnaire (IBS-SQ). Feces donated by healthy relatives of the patients were
transplanted via gastroscope. Biopsies were taken from the descending part of the
duodenum at baseline and 3 weeks after FMT. They were immunostained for neurogenin
3, Musashi 1, and all types of duodenal enteroendocrine cells and quantified by
computerized image analysis. Microbiota analyses of feces collected just before and 3
weeks after FMT were performed using GA-map™ Dysbiosis test (Genetic Analysis AS,
Oslo, Norway).
Results: The total scores for IBS-SSS and IBS-SQ were significantly improved 3 weeks
after receiving FMT, P = 0.0009 and <0.0001, respectively. The stem cell densities ofgy | www.frontiersin.org May 2021 | Volume 11 | Article 5248511
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Frontiers in Cellular and Infection Microbioloneurogenin 3 increased significantly following FMT (P = 0.0006) but not for Musashi 1 (P =
0.42). The cell densities of chromogranin A, cholecystokinin, gastric inhibitory peptide,
serotonin, and somatostatin, but not for secretin, have significantly changed in both IBS
groups after 3 weeks from receiving FMT.
Conclusion: More than two-thirds of IBS patients experienced improvement in their
symptoms parallel to changes in the enteroendocrine cells densities 3 weeks after FMT.
The changes in the enteroendocrine cell densities do not appear to be caused by changes
in the stem cells or their early progenitors rather by changes in the differentiation progeny
as detected by neurogenin 3. The study was retrospectively registered at ClinicalTrials.gov
(ID: NCT03333291).
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03333291.Keywords: cell densities, duodenum, neuroendocrine, fecal microbiota transplantation, gut hormones, microbiota,
irritable bowel syndrome, stem cellsINTRODUCTION
The neuroendocrine peptides/amines produced by the
enteroendocrine cells regulate several functions of the
gastrointestinal (GI) tract such as motility, secretion,
absorption, visceral sensitivity, local immune-defense, cell
proliferation, and appetite (El-Salhy et al., 2014; El-Salhy et al.,
2017). The enteroendocrine cells possess sensory tentacle
protruding into the intestinal lumen that sense the changes in
the intestinal lumen and respond by releasing their
neuroendocrine peptides/amines (Sternini et al., 2008; El-Salhy
et al., 2016). Enteroendocrine cells, stem cells, and their
progenitor cells are abnormal in the proximal and distal parts
of the small intestine of patients with irritable bowel syndrome
(IBS) (Dizdar et al., 2010; El-Salhy et al., 2010; El-Salhy et al.,
2014a; El-Salhy, 2015; El-Salhy and Gilja, 2017). The
abnormalities in enteroendocrine cells seem to explain the
dysmotility, visceral hypersensitivity, and abnormal intestinal
secretion seen in IBS patients (El-Salhy et al., 2014).
Patients with IBS also have an altered gut microbiota profile
(Carroccio et al., 2010; Ohman and Simren, 2013; Hong and
Rhee, 2014) i.e.; fewer Lactobacillus and Bifidobacterium spp. and
more Clostridium spp. that ferment fibers and fermentable
oligosaccharides, disaccharides and monosaccharides, and
polyols (FODMAPs), and produce gas leading to luminal
distension with symptoms of the abdominal pain and bloating
(Si et al., 2004; Kassinen et al., 2007; El-Salhy et al., 2014b).
Probiotics (live bacterial cultures) have been used to alleviate the
symptoms of IBS (Sisson et al., 2014), but unfortunately, they
have shown limited effectiveness (Malikowski et al., 2017).
Human feces from a healthy subject are used to treat patientsCCK, Cholecystokinin; FMT, Fecal
P, fermentable oligosaccharides,
ols; GI, Gastrointestinal; GIP, Gastric
ndrome; PI, post-infectious; IBS-SQ,
estionnaire; IBS-SSS, Irritable Bowel
, Musashi 1; NEUROG3, neurogenin
gy | www.frontiersin.org 2with recurrent Clostridium difficile colitis through re-establishing
the balance in the gut microbiota (van Nood et al., 2013). A new
concept is emerging where FMT is used as a treatment option for
IBS symptoms (Pinn et al., 2014; Halkjaer et al., 2018; Johnsen
et al., 2018; Mazzawi et al., 2018; El-Salhy et al., 2019).
The gut microbiota affect both the enteroendocrine cells and
the enteric nervous system (Reigstad et al., 2015; Greiner and
Backhed, 2016). A published study by our group (Mazzawi et al.,
2018) has shown that using FMT in IBS patients reduces their
symptoms, improves their quality of life within the first week,
and restores the imbalance in the gut microbiota within 3 weeks,
which lasts for 28 weeks after receiving FMT. The mechanisms
behind this improvement are still unknown. The aim of this
study was to investigate whether the improvement brought about
by FMT in these IBS patients was caused by the interaction of the
microbiota with the stem or/and enteroendocrine cells. Thus, the
possible changes in the densities of Musashi 1 (Msi-1, a marker
for stem cells and their early progenitors) (Bjerknes and Cheng,
2006), neurogenin 3 (NEUROG3, a marker for enteroendocrine
cells progenitor) (Montgomery and Breault, 2008), and
enteroendocrine cells in IBS patients following FMT
were studied.MATERIALS AND METHODS
Patients, Donors, and Controls
A recipient group of 16 IBS patients who met the Rome III criteria
for IBS and were referred to the gastroenterology outpatient clinic,
Haukeland University Hospital, Bergen, Norway during the year of
2015 were included in the study. The patients had moderate to
severe abdominal symptoms as defined by IBS-Symptom Severity
Scoring system (IBS-SSS) score >175. The exclusion criteria
included history of inflammatory bowel diseases, GI malignancy,
blood in stool, immunocompromised patients who are taking
immunosuppressive medications, history of opportunistic
infections within 1 year prior to FMT, oral thrush, or
disseminated lymphadenopathy. Patients who were scheduled forMay 2021 | Volume 11 | Article 524851
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taking probiotics or antibiotics within 1 month prior to FMT
were also excluded.
A donor group of healthy family members, seven males and
nine females with an age range 20–55 (mean age 35) years were
also included. The exclusion criteria of the donors were
pregnancy, history of inflammatory bowel diseases, IBS,
chronic abdominal pain, GI malignancy, diarrhea, blood in
stool, antibiotic and probiotic use within 1 month prior to
FMT, immunocompromised patients who were consuming
immunosuppressive medications, history of opportunistic
infections within 1 year prior to FMT, oral thrush, and
disseminated lymphadenopathy.
Biopsy samples from a group of 12 healthy volunteers, 10
females and two males with an age range 20–42 (mean age 39)
years, recruited at Stord Hospital, Stord, Norway by advertising
in the local newspapers, were used as controls to study duodenal
stem cells and enteroendocrine cells.
The study was performed in accordance with the Declaration
of Helsinki (World Medical Association Declaration of Helsinki,
2013), adhered to CONSORT guidelines and was approved by
the Regional Committee for Medical and Health Research Ethics
in Western Norway (reference no.: 2013/1497). The current
study was retrospectively registered on 03.Nov.2017 at
ClinicalTrials.gov (ID: NCT03333291). All of the participants
provided written informed consent.
Study Design
The donors and patients were screened one week before FMT
according to the reviews and guidelines that were published prior to
the start of the study in the year 2015 (Aroniadis and Brandt, 2013;
Cammarota et al., 2014). They were physically examined, and blood
tests were taken to investigate previous exposure to contagious
infectious agents including serologic testing for the donors (hepatitis
A, B and C, HIV, Epstein–Barr virus and cytomegalovirus) and for
the patients [hemoglobin, leucocytes, platelets, creatinine, aspartate
aminotransferase, alanine aminotransferase, International
normalized ratio (INR), chromogranin A (CgA), and electrolytes].
Stool samples from both donors and patients were examined for
fecal calprotectin, cultured for enteric bacterial pathogens, and
screened for viruses, parasites, and eggs. The patients were told
not to change their lifestyle or diet before the start or during the
study and to report any changes in their lifestyle or use of new
medications during the study.
FMT Procedure
On transplantation day, 30 g of fresh donors’ feces (<2 h from
production to donation) was mixed with 60 ml normal saline for
preparing the fecal suspension using manual effort and sieved in
order to avoid the clogging of infusion syringes and tubes
(Aroniadis and Brandt, 2013; Cammarota et al., 2014). All of
the patients fasted overnight and received only once a 60 ml of
fecal suspension followed by 60 ml normal saline, using a 60 ml
syringe, infused through the gastroscope into the descending part
of the duodenum past the duodenal papilla at a steady rate within
7–10 seconds to avoid a fast flush and regurgitation of fecal
material into the stomach. Tissue biopsies were taken from theFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3descending part of the duodenum before installation of feces and
again 3 weeks after FMT. Fecal samples were collected on the
same day of FMT (before the procedure) and 3 weeks after FMT
and sent for microbiota analysis using GA-map™ Dysbiosis test
(Genetic Analysis AS, Oslo, Norway) as previously explained in
details (Mazzawi et al., 2018).
Questionnaires
The patients completed the following questionnaires before and
3 weeks after FMT for IBS symptoms assessment: a) IBS-
Symptom Severity Scoring system (IBS-SSS), in which higher
scores indicated worse symptoms (scores <175 represented mild
IBS symptoms, 175–300 moderate severity, and >300 severe IBS)
and a decrease of 50 points correlated with improvement in
clinical symptoms (Francis et al., 1997), and b) IBS symptom
questionnaire (IBS-SQ) reported IBS symptoms (nausea,
bloating, abdominal pain, constipation, diarrhea, and anorexia)
using a severity scale from 0 to 10, where 0 = no symptoms and
10 = severe symptoms (Mathias et al., 1994; Kane et al., 2003).
Gastroscopy and Immunohistochemistry
The patients fasted overnight prior to undergoing a gastroscopy.
During the gastroscopy, four tissue biopsies were collected from the
descending part of the duodenum, distal to the papilla. The biopsy
samples were fixed in 4% buffered paraformaldehyde, paraffin-
embedded biopsies were cut into 5 mm thick sections. The
sections were then stained with hematoxylin–eosin and
immunostained with an ultraView Universal DAB Detection Kit
(cat.no. 760-500, Ventana Medical Systems, Basal, Switzerland) and
the BenchMark Ultra IHC/ISH staining module (Ventana Medical
Systems). The sections were incubated with the primary antibodies
for 32 min at 37°C. The primary antibodies that were diluted
according to the suppliers’ recommendations were as follows:
polyclonal rabbit anti-synthetic peptide conjugated to keyhole
limpet hemocyanin derived from within residues 1–100 of human
Msi-1 (code ab21628, Abcam, Cambridge, United Kingdom),
monoclonal mouse-anti-protein expressed in 293T cells
transfected with human NEUROG3 expression vector (code
ab87108, Abcam), monoclonal mouse antibody raised against the
N-terminal of purified CgA (code no. M869, Dako, Glostrup,
Denmark), polyclonal rabbit anti-human secretin for the detection
of secretin (code no. sc-20938, Santa Cruz Biotechnology, Santa
Cruz, CA, United States), rabbit antibodies for the detection of
cholecystokinin (CCK; code no. A0568, Dako, Glostrup, Denmark),
mouse antibodies against human synthetic gastric inhibitory peptide
(GIP; code no. sc-57162, Santa Cruz Biotechnology), mouse
antibodies against serotonin (code no. R87104 B56-1, Dako), and
rabbit antibodies against synthetic cyclic somatostatin (code no.
A0566, Dako). Labeled secondary antibodies locate the specific
antibody. The complex is then visualized with hydrogen peroxide
substrate and 3, 3′-diaminobenzidine tetrahydrochloride (DAB)
chromogen, which produces a brown precipitate, and
counterstained with hematoxylin.
Computerized Image Analysis
1) The densities of Msi-1 and NEUROG3 were quantified using
×40 objective on the light microscope equipped with a digitalMay 2021 | Volume 11 | Article 524851
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equipped with a software cellSens imaging program (version 1.7,
Olympus, Tokyo, Japan). The number of immunoreactive cells and
crypts was quantified in 10 randomly chosen fields. Each field
(frame) represented a tissue area of 0.035 mm2. Msi-1 cell density is
expressed as the number of cells/10 crypts and the density of
NEUROG3 as number of cells/field.
2) Enteroendocrine cell densities were quantified using a light
microscope with ×40 objective and a computer software Cell^B
imaging program (Olympus, Tokyo, Japan). The number of
immunoreactive cells was quantified in 10 randomly chosen
fields. Each field (frame) of epithelial cells represents a tissue area
measured at 0.09 mm2. The density of each enteroendocrine cell
type was expressed as the number of cells/mm2 of epithelium.
By keeping the identity of the slides concealed, the quantification
of Msi-1 and NEUROG3 was performed by M.E.S., and the
quantification of the enteroendocrine cells was performed by T.M.
Gut Microbiota Analysis
The gut microbiota analysis was previously described in details
(Mazzawi et al., 2018). Briefly, GA-map™Dysbiosis test is based on
fecal homogenization, mechanical bacterial cell disruption, and
automated total bacterial genomic DNA extraction using
magnetic beads. Fifty-four DNA probes were used targeting more
than 300 bacterial strains based on their 16S rRNA sequence in
seven variable regions (V3–V9). Twenty-six bacteria probes are
species specific, 19 detect bacteria on the genus level, and nine
probes detect bacteria at higher taxonomic levels. Probe labeling is
by single nucleotide extension and hybridization to complementary
probes coupled to magnetic beads and signal detection by using
BioCode 1000A 128-Plex Analyzer (Applied BioCode, Santa Fe
Springs, CA, USA) (Casen et al., 2015).
Statistical Analysis
Kruskal–Wallis with Dunn’s post hoc test was used to compare the
cell densities between the controls and the patients before and after
receiving FMT. Paired t-test is used to compare between the cell
densities of the patients before and after receiving FMT. Mann–
Whitney U test was used to compare the microbiota profiles of the
patients before and after FMT to their respective donors.
Correlations were performed using Spearman non-parametric
test. The data are presented as mean ± SEM values. P <0.05 is
considered to be statistically significant.RESULTS
Patients
Four out of the 16 originally included patients were excluded
after withdrawing their consents to participate for practical
reasons (n = 1), failed gastroscope intubation after FMT
(n = 1), being diagnosed with functional dyspepsia (n = 1),
and positive stool culture for Clostridium difficile (n = 1). The
remaining patients (n = 12) were four females and eight males,
with age range 20–44 years. Six patients suffered from post-
infectious IBS (PI-IBS), and six had idiopathic IBS. They
completed the whole study by filling out the questionnairesFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4and delivered stools for microbiota analysis at the same day of
undergoing gastroscopy with duodenal biopsies i.e. the day of
FMT and after 3 weeks. No change in lifestyle, diet, or use of any/
new medications has been registered during the study.
Questionnaires
Three weeks following FMT, the symptoms of IBS as assessed by
IBS-SSS improved in 9/12 (75%) of total IBS patients, 5/6 (83.3%) of
PI-IBS and 4/6 (66.6%) of idiopathic IBS patients. The total scores
of the questionnaires showed a significant reduction from before
FMT to 3 weeks after FMT as follows: IBS-SSS (326.6 ± 22.3 and
240.2 ± 33.6, respectively, P = 0.0009) and IBS-SQ (30.8 ± 3.3 and
11.6 ± 2.1, respectively, P < 0.0001). The scores of the different
domains of IBS-SQ are shown in Table 1, which show a significant
improvement in all of its domains except for anorexia.
Gastroscopy and Immunohistochemistry
The duodenum of the patients was normal both endoscopically and
microscopically. Msi-1 immunoreactivity was observed in both the
cytoplasm and nucleus, and immunoreactive cells were found in the
crypts of the duodenum. NEUROG3 immunoreactivity was found
exclusively in the nuclei of cells that were observed in both the
crypts and along side the villi. The immunoreactive enteroendocrine
cells; CgA, secretin, CCK, GIP, somatostatin, and serotonin, were
localized mostly in the crypts.
Computerized Image Analysis
The densities of the stem cells and the enteroendocrine cells in
the duodenum in controls and IBS patients are shown in Tables
2 and 3, respectively, before and after receiving FMT. The
densities of the immunoreactive cells before and after FMT are
shown in Figures 1 and 2 for NEUROG3 and Figure 3 for Msi-1.
The cell densities of NEUROG3 were significantly lower (P =
0.04) for the total group of IBS patients before FMT than
controls, but no significant difference was shown after FMT
(P = 0.47). The cell densities of Msi-1 for the total group of IBS
patients before and after FMT were significantly lower than the
controls (P = 0.046 and 0.004, respectively). No significant
changes were shown in the NEUROG3 and Msi-1 cells
densities for both subgroups before and after FMT compared
to controls (except for Msi-1 cell densities in idiopathic IBS after
FMT, P = 0.02). When we compared cell densities for the patientsTABLE 1 | The scores of IBS-symptom questionnaire (IBS-SQ) domains in
patients with irritable bowel syndrome.
Questionnaire Before FMT 3 weeks after FMT P-value
Nausea 3.7 ± 0.9 1.4 ± 0.6 0.0025
Bloating 7.9 ± 0.5 3.4 ± 0.8 <0.0001
Abdominal pain 6.3 ± 0.9 3.3 ± 0.8 0.0012
Constipation 4.3 ± 1.1 1.5 ± 0.7 0.046
Diarrhea 6.4 ± 0.9 1.2 ± 0.4 <0.0001
Anorexia/loss of appetite 2.3 ± 0.7 0.9 ± 0.4 0.087May 2021 | Volume 11 | ArticleData are presented as the mean ± SEM. Comparison: Paired t test. FMT, fecal microbiota
transplantation.
Significant differences are seen in the different domains (except for anorexia/loss of
appetite) when comparing the symptoms of the patients before to after FMT.
The bolded numbers are significant values <0.05.524851




















After, n = 12
PI-IB
before,
13.8 394.3 ± 30.7 214.2 ± 0.47 0.1 0.2 0.1 0.99 0.0006 0.0007 0.1
0.4 5 ± 0.5 5.3 ± 0.004 0.07 0.05 0.2 0.02 0.42 0.9 0.2
Comparison: Kruskal–Wallis with Dunn’ ients after FMT, ccontrols vs. PI IBS patients before FMT, dcontrols vs. PI
pathic IBS patients before FMT, fcontro fore vs. after FMT, hPI-IBS patients before vs. after FMT, iIdiopathic IBS
l microbiota transplantation; IBS, irritab
es <0.05.


















, n = 12
Total IBS,
After, n = 12
PI-I
before
± 21 269.8 ± 22 340.8 0.0133 0.2 0.006 0.005 0.4 0.98 0.0006 0.0065
± 4.9 86.7 ± 5.9 80.5 ± 0.21 0.99 0.5 0.1 0.3 0.5 0.099 0.6
± 6.7 110.7 ± 8.1 113 ± 0.023 0.055 0.005 0.0008 0.5 0.2 0.052 0.0006
± 3.8 70.3 ± 6.2 60 ± 3 0.19 0.96 0.01 0.2 0.99 0.5 0.014 0.2
± 14.7 142 ± 12.8 100.5 0.0088 0.7 0.005 0.01 0.2 0.7 0.012 0.034
± 4 66.2 ± 6.3 52.3 ± 0.012 0.3 0.006 0.03 0.3 0.3 0.011 0.017
parison: Kruskal–Wallis with Dunn’s p ts after FMT, ccontrols vs. PI IBS patients before FMT, dcontrols vs. PI IBS
S patients before FMT, fcontrols vs. idio r FMT, hPI-IBS patients before vs. after FMT, IIdiopathic IBS patients before













































340 ± 40 222.3
Musashi 1 8.75 ±
0.95
5.7 ±
Data are presented as the mean ± SEM.
IBS patients after FMT, econtrols vs. idio
patients before vs. after FMT. FMT, feca
The bolded numbers are significant valu






Chromogranin A 228 ±
33.6
370.
Secretin 74 ± 3.8 83.8













Data are presented as the mean ± SEM. Co
patients after FMT, econtrols vs. idiopathic IB
vs. after FMT. FMT, fecal microbiota transp













after, n = 6
Idiopathic IBS,
before, n = 6
Idiopathic IBS,
after, n = 6
8.5 430.5 ± 28.9 230.5 ± 21.5 358.2 ± 52.9 0.004
7 5.2 ± 0.8 6 ± 0.4 4.8 ± 0.7 0.046
ost test, acontrols vs. total IBS patients before FMT, bcontrols vs. total IBS pat
s. idiopathic IBS patients after FMT; and Paired t test, gtotal IBS patients be
owel syndrome. PI, post-infectious.
l IBS group, PI-IBS, and idiopathic IBS patients before and after receiv





after, n = 6
Idiopathic IBS,
before, n = 6
Idiopathic IBS,
after, n = 6
34 422.7 ± 31 399.8 ± 20.9 316.8 ± 10.2 0.0099
.8 89.7 ± 10.7 87.2 ± 4.8 83.7 ± 5.9 0.32
.4 126.5 ± 0.5 132.5 ± 7.2 94.8 ± 9 0.0007
3.7 84 ± 7.1 69.8 ± 6.3 57.2 ± 7 0.33
.1 160.7 ±
16.6
169.7 ± 20.6 123.3 ± 17.3 0.04
.7 78.5 ± 8.1 64.8 ± 7 53.8 ± 6.8 0.033
test, acontrols vs. total IBS patients before FMT, bcontrols vs. total IBS patien






















Mazzawi et al. FMT, Stem, and Enteroendocrine Cellsbefore to after FMT, significant changes were seen in the cell
densities of NEUROG3 densities for the total group of IBS and
PI-IBS patients (P = 0.0006 and 0.007, respectively) but not for
idiopathic IBS subgroup. No changes were seen in the Msi-1 cell
densities when comparing IBS patients before and after FMT in
all groups, Table 2. Several enteroendocrine cells showed
significant differences in their cells densities compared to
controls except for secretin (Figure 4) and GIP. The densities
of the enteroendocrine cells increased in PI-IBS and decreased inFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6the idiopathic IBS subgroup following FMT compared to before
FMT. The directions of these changes were either towards or
away from the values measured for controls, Table 3.
Gut Microbiota
The analysis of the gut microbiota for the total group of IBS
patients has been previously described (Mazzawi et al., 2018). In
the current study, patients with PI-IBS before FMT had a
significant increase in the bacterial signals for StreptococcusFIGURE 2 | Neurogenin 3 immunoreactive cells in patients with irritable bowel syndrome (A) before and (B) after fecal microbiota transplantation.A B
C
FIGURE 1 | Neurogenin 3 cell densities before and after fecal microbiota transplantation (FMT) in (A) total, (B) post-infectious and (C) idiopathic irritable bowel
syndrome patients. The dotted line represents the mean cell densities for the healthy control group. *** indicates P < 0.001.May 2021 | Volume 11 | Article 524851
Mazzawi et al. FMT, Stem, and Enteroendocrine Cellscompared to donors at the beginning of the study and
significantly reduced bacterial signals for Megasphaera/
Dialister, Actinobacteria, and Bifidobacterium compared to
donors at the beginning of the study, Table 4. Patients with
idiopathic IBS before FMT had a significant decrease in the
bacterial signals for Firmicutes/Tenericutes/Bacteroidetes,
Megasphaera/Dialister, Actinobacteria, Bifidobacterium, and
Actinomycetales compared to donors at the beginning of the
study, Table 4.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7Correlations
The correlation coefficient (r) and value of significance (P) for
NEUROG3 cells with secretin were r = −0.89, P = 0.033 after
FMT in the PI-IBS subgroup, and for NEUROG3 cells with
serotonin were r = 0.89, P = 0.03 before FMT, and also with CCK
were r = 0.89, P = 0.03 after FMT in the idiopathic IBS subgroup.
Certain strains of the gut microbiota correlated with stem and
enteroendocrine cells. Before FMT, Parabacteriodes correlated with
NEUROG3 cells in the total group (r = 0.76, P = 0.037) and withFIGURE 4 | Secretin immunoreactive cells in patients with irritable bowel syndrome (A) before and (B) after fecal microbiota transplantation.A B
C
FIGURE 3 | Musashi 1 cell densities before and after fecal microbiota transplantation (FMT) in (A) total, (B) post-infectious and (C) idiopathic irritable bowel
syndrome patients. The dotted line represents the mean cell densities for the healthy control group.May 2021 | Volume 11 | Article 524851
Mazzawi et al. FMT, Stem, and Enteroendocrine CellsGIP cells in the PI-IBS group (r = 0.89, P = 0.03). In the PI-IBS
subgroup, inverse correlations were found between Streptococcus
sanguinis and thermophiles and the following: CgA (r = −0.94, P =
0.017), CCK (r=−0.89,P=0.03), and serotonin (r =−0.89,P=0.03)
cells and between Actinobacteria and CgA (r = −0.89, P = 0.03),
CCK (r = −0.94, P = 0.017) and serotonin (r = −0.94, P = 0.02) cells.
After FMT, a correlation was found between NEUROG3 cells and
Actinobacteria (r = 0.79, P = 0.025) also Bifidobacterium (r = 0.79,
P = 0.025) in the total group of IBS patients and between GIP cells
andActinobacteria (r = −1, P = 0.017) also Bifidobacterium (r = −1,
P = 0.017) in the idiopathic-IBS subgroup. In addition, correlations
were found between Lactobacillus and NEUROG3 cells (r = 0.75,
P = 0.038) in the total group of IBS patients and also
somatostatin cells (r = 1, P = 0.017) in the idiopathic-IBS group.
No correlations were found between Msi-1 and gut microbiota
before or after FMT in any group of IBS patients.
The correlations between IBS symptoms using IBS-SQ
questionnaire and the different enteroendocine cells were as
follows: before FMT, pain correlated with the cell densities of
each of CgA (r = 0.87, P = 0.02), serotonin (r = 0.87, P = 0.02)
and CCK (r = 0.92, P = 0.01) and anorexia correlated with GIP
(r = 0.91, P = 0.01) in the PI-IBS subgroup. In addition, bloating
correlated with CgA (r = 0.85, P = 0.03), anorexia correlated with
each of secretin (r = −0.91, P = 0.01) and GIP (r = −0.95,
P=0.003), and nausea correlated with each of CCK (r= –0.89,
P=0.01) and GIP (r= –0.95, P=0.003) in the idiopathic IBS
subgroup. After FMT, diarrhea correlated with secretin (r =
0.83, P = 0.04) in PI-IBS and nausea with CCK cell density (r =
−0.89, P = 0.02) in the idiopathic IBS subgroup.
Adverse Events
No adverse events were reported during or following FMT.
DISCUSSION
In this study, the changes in IBS symptoms are associated with
changes in the densities of the enteroendocrine cells and their
progenitors NEUROG3 in the duodenum and in the gut
microbiota of these patients 3 weeks after receiving FMT.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8As previously reported (Mazzawi et al., 2018), approximately
75% of the total IBS patients showed improvement in their IBS
symptoms following FMT. The densities of stem cells and
enteroendocrine cells in the duodenum are abnormal in IBS
patients before FMT, which is consistent with previous
publications (El-Salhy et al., 2010; El-Salhy et al., 2014c; El-Salhy
et al., 2015). Significant changes were mainly seen in the densities of
NEUROG3 but not Msi-1 cells and all of the enteroendocrine
(except for secretin) cells in IBS patients 3 weeks following FMT
compared to before FMT. This indicates that the changes in the
enteroendocrine cell densities are caused by a change in the
differentiation of stem cells into enteroendocrine cells (as
presented by NEUROG3). The observation that gut microbiota
influence the differentiation of stem cells into enteroendocrine cells
has been previously reported in the jejunum and colon of mice
(Cani et al., 2007; Everard et al., 2011; Wichmann et al., 2013; Cani
and Knauf, 2016). However, the exact mechanism explaining how
the gut microbiota shape the fate of stem cells into enteroendocrine
cells remains unknown.
A previous study showed that the CgA cell density, a common
marker for endocrine cells (Deftos, 1991; Taupenot et al., 2003),
correlated with NEUROG3 cell density in the small intestine of
IBS patients (El-Salhy and Gilja, 2017). The correlations between
the stem cells and enteroendocrine cells may be explained by that
all of the enteroendocrine cells types arise from endocrine
progenitors expressing NEUROG3 then the opposing activities
of Pax4- and Arx-homeodomain transcription factors (Beucher
et al., 2012). The inactivation of Pax4 leads to the up-regulation
of Arx and the differentiation of these progenitors into different
types of enteroendocrine cells and vice versa. Serotonin-
producing enterochromaffin cells can differentiate in a
NEUROG3 dependent and independent pathway. Similar to
serotonin, somatostatin cells are generated from progenitors
expressing NEUROG3 then Pax4. GIP-, secretin-, and CCK-
cells arise from endocrine progenitors expressing NEUROG3
then Pax4 and Arx. The inactivation of Arx can cause these
progenitors to be reallocated into the expression of somatostatin
cells while GIP-, secretin-, and CCK-cells’ expression becomes
impaired. However, an inactivation of Pax4 leads to an up-TABLE 4 | Fecal bacterial strains for donors at the beginning of the study and post-infectious IBS and idiopathic IBS patients before and after FMT.
Bacteria strain Donors Patients P-values* P-values**
Before FMT Week 3 after FMT
Post-infectious IBS
Streptococcus 47 (41, 59) 88 (59, 114) 79 (44, 210) 0.038 0.26
Megasphaera/Dialister 162 (58, 286) 19 (3, 57) 10 (5, 143) 0.038 0.11
Actinobacteria 160 (99, 321) 61 (21, 73) 219 (107, 435) 0.0095 0.9
Bifidobacterium 160 (96, 370) 62 (19, 86) 212 (92, 447) 0.019 0.9
Idiopathic IBS
Firmicutes/Tenericutes/Bacteroidetes 260 (103, 475) 51 (24, 134) 133 (14, 279) 0.048 0.18
Megasphaera/Dialister 4 (3.8, 247) 3.3 (3, 3.6) 3.1 (2.7, 98) 0.048 0.37
Actinobacteria 296 (251, 499) 89 (36, 115) 89 (44, 268) 0.0025 0.02
Bifidobacterium 358 (256, 645) 70 (38, 110) 100 (45, 282) 0.0025 0.02
Actinomycetales 15 (11, 18) 8.4 (8.1, 13) 13 (10,24) 0.03 0.95May 2021 | Volume 11 | ArtData are presented as the median (first, third quartiles). Comparison: Mann-Whitney U test. * donors compared to patients before FMT and ** donors compared to patients after FMT. FMT,
fecal microbiota transplantation; IBS, irritable bowel syndrome.
The bolded numbers are significant values <0.05.icle 524851
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into L cells (producing glucagon-like peptide-1 and peptide YY),
while the differentiation of somatostatin-, serotonin-, and GIP-
cells becomes impaired (Beucher et al., 2012). Therefore, the
positive correlations between NEUROG3 cell densities and the
different enteroendocrine cells along with the negative
correlation between NEUROG3 cell density with secretin cell
density, before and after FMT in the different IBS subgroups,
may be attributed to the progenitor differentiation to other
enteroendocrine cell types as previously explained. The
densities of the enteroendocrine cells in the duodenum have
changed 3 weeks following the FMT procedure. On one hand,
the changes in the idiopathic-IBS patients are towards the
healthy controls, which is similar to a previous study by our
group using diet in managing IBS symptoms (Mazzawi and El-
Salhy, 2017a; Mazzawi and El-Salhy, 2017b). On the other hand,
the cell densities in PI-IBS patients increase away from the values
measured for healthy controls, which may be due to the
infectious origin of IBS in these patients (Dizdar et al., 2010).
The alterations in the strain signals of the gut microbiota have
become normal after 3 weeks following FMT except for
Actinobacteria and Bifidobacterium, which showed some changes
towards normal but remained significantly different in the
idiopathic IBS subgroup compared to the donors. The bacteria
that correlated with the changes in the differentiation of stem cells
into enteroendocrine cells as detected by NEUROG3 namely,
Parabacteroides , Actinobacteria, Bifidobacterium , and
Lactobacillus, also correlated with different enteroendocrine cells
before and after FMT in the different groups. The changes in the
bacterial strain signals occurred parallel to the changes in the
differentiation progeny of stem cells and enteroendocrine cells
densities, which indicated that gut microbiota might influence
other enteroendocrine cell types than the previously reported
enterochromaffin and L cells (Everard et al., 2011). This may also
have shed some light on the mechanisms lying behind FMT and the
positive effects of using these bacterial strains in the management of
IBS symptoms (Whorwell et al., 2006; Drouault-Holowacz et al.,
2008; Bixquert Jimenez, 2009; Sisson et al., 2014). The gut
microbiota interact with the enteroendocrine cells through their
microbial metabolites, short-chain fatty acids (especially butyrates)
(Nohr et al., 2013; Cani and Knauf, 2016). Searching for a
mechanism of action, we reasoned that because the vast majority
of the gut microbiota are located in the ileum and in the colon and
due to the paracrine and endocrine functions of the enteroendocrine
cells throughout the gastrointestinal tract, the beneficial effects of
FMT on the gut microbiota and their products (short-chain fatty
acids mainly butyrate) (Mazzawi et al., 2019) might be related but
not exclusive to this area of the gastrointestinal tract.
Visceral hypersensitivity plays an important role in the
pathogenesis of upper gastrointestinal symptoms especially
nausea, abdominal bloating and pain (Salet et al., 1998).
Correlations of pain with serotonin and CCK cells can be
explained since serotonin and CCK are involved in sensory
and motor responses to distension in the intestinal tract and so
perception of pain in IBS (Varga et al., 2004; Wendelbo et al.,
2014). Although negatively correlated in this study, CCK is aFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 9satiety hormone and is involved in anorexia and nausea (Chua
and Keeling, 2006; El-Salhy et al., 2014). GIP correlates
negatively with anorexia (Stock et al., 2005) and does not
induce nausea (Mentis et al., 2011). Secretin contributes to the
rapid gastric emptying and pancreatic bicarbonate and fluid
secretions therefore diarrhea in IBS (El-Salhy et al., 2014).
Two recently published meta-analyses have shown that fresh
or frozen donor stool delivered via colonoscopy or nasojejunal
tube may be beneficial in IBS (Xu et al., 2019; Ianiro et al., 2019).
A newly published randomized, double-blinded, placebo-
controlled study using a large cohort of IBS patients show that
transplanting frozen stool via a gastroscope is an effective
treatment for IBS patients (El-Salhy et al., 2019). In the current
study, we have chosen to use gastroscopy because it is an easy
and fast procedure and because patients with IBS often have
small intestinal bacterial overgrowth, which would have escaped
the suspension, had we chosen to use colonoscopy for FMT. The
amount of transplanted fecal material, 30 g, used in this study is
consistent with the published recommendations (Aroniadis and
Brandt, 2013; Cammarota et al., 2014) before the starting point of
the study in 2015 and with the European consensus on FMT
(Cammarota et al., 2017). According to the newly published
study (El-Salhy et al., 2019), both 30 g and 60 g FMT have shown
significant responses compared to placebo in IBS patients.
No adverse events were noted following FMT in the current
study despite previous data of minor adverse events that resolved
spontaneously (El-Salhy and Mazzawi, 2018). We have previously
published about the daily changes that occur to these symptoms
during the first 3 days and 7 days following FMT, which showed a
dramatic improvement in IBS symptoms shortly after FMT
(Mazzawi et al., 2018). One can hypothetically assume that due to
the severity of IBS symptoms before FMT, either that the patients
did not relate to any worsening of their originally experienced
bothersome symptoms or that they actually have benefited from the
FMT with rapid improvement of the aforementioned symptoms.
The strength of the current study is the usage of validated
methods to study the changes in the gut microbiota and
immunoreactive cells’ densities and validated questionnaires to
assess the changes in IBS symptoms. However, there are several
limitations, such as the small number of the participants and the
lack of a placebo-control group from which tissue biopsies could
have been taken for the study of the stem and enteroendocrine
cells. In spite of the small sample size of the different IBS groups,
we found significant differences in the immunoreactive cells’
densities before and after FMT. However, further studies with
larger groups of participants are required to be able to draw firm
conclusions regarding the effect of FMT on the stem and
enteroendocrine cells’ densities.CONCLUSIONS
Fecal microbiota transplantation improves the symptoms after 3
weeks in of IBS patients, both PI and idiopathic IBS. This
improvement is associated with a change in the enteroendocrine
cell density and the gut microbiota. The changes in theMay 2021 | Volume 11 | Article 524851
Mazzawi et al. FMT, Stem, and Enteroendocrine Cellsenteroendocrine cell density do not appear to be caused by changes
in the stem cells or their early progenitors but rather by changes in
the differentiation progeny as detected by changes in neurogenin 3.DATA AVAILABILITY STATEMENT
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